Evidence supporting the use of: Acetyl L-carnitine
For the health condition: Autism

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Acetyl L-carnitine (ALC) has been studied as a potential adjunctive treatment for autism spectrum disorder (ASD), primarily due to its role in cellular energy metabolism and possible neuroprotective effects. A few small-scale clinical trials have explored its efficacy. Notably, a randomized, double-blind, placebo-controlled study published in 2008 (by Geier et al.) evaluated ALC supplementation in children with ASD and intellectual disabilities. The study found some improvements in social behavior, attention, and language in the ALC group compared to placebo, especially among children with lower baseline carnitine levels. However, the sample size was limited, and results have not been widely replicated. The rationale for ALC supplementation is also supported by the observation that some children with ASD may have mitochondrial dysfunction or lower carnitine levels, which could theoretically benefit from carnitine supplementation. Nevertheless, the evidence remains preliminary. Most expert guidelines do not endorse ALC as a standard therapy for ASD, citing the need for larger, well-designed trials to confirm efficacy and safety. In summary, there is some scientific investigation into ALC for autism, but the overall quality and quantity of supporting evidence are limited. Use should be considered experimental, and always under medical supervision.

More about Acetyl L-carnitine
More about Autism